Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of a Therapeutic Vaccine for Malignancies, Comprising the Tumor Antigen NY-ESO-1 in Combination With the Adjuvant MPLA of Bordetella Pertussis. Evaluation of Toxicity and Immunogenicity

NCT01584115 is registered in ClinicalTrials.gov with Instituto de Investigação em Imunologia as lead sponsor.

NCT NCT01584115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01584115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of a Therapeutic Vaccine for Malignancies, Comprising the Tumor Antigen NY-ESO-1 in Combination With the Adjuvant MPLA of Bordetella Pertussis. Evaluation of Toxicity and Immunogenicity
Lead sponsor
Instituto de Investigação em Imunologia
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2012
Completion date
July 31, 2013
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer., lung cancer., melanoma., ovarian cancer.